Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB000928 Monotherapy or in Combination With Ruxolitinib in Anemia Due to Myeloproliferative Disorders
NCT04455841Phase 2Completed
- Sponsor
- Incyte
- Start
- Mar 2021
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label trial of zilurgisertib in anemia (3 arms), sponsored by Incyte. Primary endpoints: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) and Any Treatment-emergent Serious Adverse Event (SAE), Number of Participants With Any >=Grade 3 TEAE and Any Treatment-emergent SAE and 3 more. Started Mar 2021; status: completed.
02
Drugs
zilurgisertib
03
Conditions
anemia
Beyond the preview
Go deeper on NCT04455841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04455841.